Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

(RTTNews) - OS Therapies, Inc. (OSTX) Wednesday announced that it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related ...

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), reducing the price target ...

Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.